Target intelligence / Profile preview

DnaJ heat shock protein family member C5 (DNAJC5)

Target
DNAJC5
Molecular classification
Co-chaperone protein, Heat shock protein (Hsp40 family), Other
01

Overview

DnaJ heat shock protein family member C5 (DNAJC5) is a neuronally enriched co-chaperone (part of the Hsp40 family), best known as cysteine-string protein alpha (CSPα), essential for synaptic function and protein homeostasis. It is primarily located on synaptic vesicles in neurons, where it helps maintain neurotransmission by refolding or stabilizing key synaptic proteins and preventing protein aggregation. DNAJC5 interacts closely with Hsp70 heat shock proteins, regulating their ATPase activity and supporting protein recycling following neurological stimulation. Pathogenic mutations in DNAJC5 cause adult-onset neuronal ceroid lipofuscinosis type 4 (CLN4), characterized by neurodegeneration due to failed synaptic protein quality control; it has also been implicated in broader neurodegenerative processes, including Huntington’s disease. DNAJC5 does not act as a conventional drug target (such as receptor, enzyme, or transporter), but is an important molecular chaperone for synaptic maintenance and may serve as a disease biomarker in research, especially for synaptic dysfunction and genetic forms of neurodegeneration.

Other names
Cysteine-string protein alpha (CSPα)Cysteine string protein (CSP)Ceroid-lipofuscinosis neuronal protein 4CLN4DNAJC5AFLJ00118FLJ13070NCL
02

Mechanism of action

Chaperone/co-chaperone facilitating refolding of denatured proteins; Regulates exocytosis by stabilizing synaptic proteins

03

Biological functions

Protein foldingRegulation of synaptic vesicle cycleMembrane traffickingChaperone-mediated protein quality controlAntineurodegenerative activityStimulated exocytosis
04

Disease associations

Neurodegenerative diseaseCeroid lipofuscinosis, neuronal, type 4 (CLN4 disease)Huntington’s diseaseCystic fibrosis
05

Safety considerations

Mutations disrupt protein quality control at synapses, causing neurodegenerative disease (CLN4)No known adverse effects from direct pharmacological targeting, as it is not a current therapeutic target
06

Interacting drugs

None known to directly target DNAJC5 as a primary drug target
07

Biomarkers

Mutations (L115R, L116del) as diagnostic markers for CLN4 diseaseDNAJC5/CSPα expression levels for neurodegenerative conditions (research use)

Beyond the preview

Go deeper on DnaJ heat shock protein family member C5 (DNAJC5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DnaJ heat shock protein family member C5 (DNAJC5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call